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ABSTRACT 
  
 HIV-1 has evolved to protect itself against the body’s innate viral defense 
mechanisms.  One such example of this phenomenon is illustrated by the viral protein vif, 
which is expressed in the later stages of infection.  Vif binds the host cell protein 
Apobec3G, a cytidine deaminase which is ectopically expressed in non-permissive cell 
lines to allow for reverse transcription of the HIV-1 viral genome.  Apobec3G has the 
ability to prevent HIV-1 replication by mutating the cDNA, so the goal of this research 
was to develop a novel technique for the expression and purification of Apobec3G.  An 
expression and purification technique was developed, and the purified Apobec3G protein 
was shown to have the capacity for binding viral Vif in vitro.  
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BACKGROUND 
 
Human Immunodeficiency Virus type 1 (HIV-1) 
 General Background and Discovery 
 The Human Immunodeficiency Virus Type 1 (HIV-1) is a lentivirus of the family 
Retroviridae.  Its infection in humans is characterized by a dramatic reduction in number 
of CD4 cells, and the developments of certain opportunistic infections, such as Kaposi’s 
sarcoma, and other malignant cancers in its hosts (Levy, 1998).  The disease is part of a 
group of diseases caused by immunosuppressive viruses including HIV-2 and SIV (SIV 
is speculated to be the virus from which HIV-1 evolved from in non-human primates) 
(Knipe and Howley, 2001).  The HIV-1 family of viruses, is also divided into three 
different groups dubbed M (major), O (outlier) and N (non-M or O); and those groups are 
also organized into a number of different sub-clades of HIV-1 which are thought to have 
evolved from recombination between subtypes and mutations resulting in the formation 
of unique viral strains (see Figure 1) (Knipe and Howley, 2001).   
 
 
Figure 1:  Genetic Subtypes of HIV-1 and Their  
Worldwide Distribution.  (A) Phylogenic 
relationships of each HIV subgroup.  Sequence 
homology was determined by comparing full-length 
pol sequences (Knipe and Howley, 2001).  (B) World 
distribution of each subtype of HIV-1 (Knipe and 
Howley, 2001). 
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 The first documented evidence of HIV infection in humans can be traced to an 
African serum sample collected in 1959, but the first acknowledged human infection with 
HIV/AIDS was documented in 1983 at the Pasteur Institute (Barre-Sinoussi et al, 1983).  
Subsequent studies recognized the fact that patients with Acquired Immunodeficiency 
Syndrome (AIDS) had similar preceding symptoms (Levy, 1998), leading scientists to 
believe that there was an etiologic agent required for the progression of AIDS.  Human T-
cell leukemia virus (HTLV) and lymphadenopathy-associated virus (LAV) were initially 
speculated to be this agent, but further investigation concluded it was a new lentivirus 
(Gallo and Montagnier, 2003) that had so many new characteristics, the International 
Committee on Taxonomy of Viruses gave it a separate name – Human Immunodeficiency 
Virus (HIV) (Coffin et al, 1986).  
 
 HIV-1 Virion 
 The HIV-1 virion has a cone shaped core that contains a genome composed of 
two identical RNA strands, molecules of viral dependent DNA polymerase (Reverse 
Transcriptase -- RT) and the nucleocapsid proteins (NC, p9) (Levy, 1998).  The 
core/nucleus is surrounded by capsid protein (CA, p24) and the accessory viral protein R 
(vpf, p15) (Gelderblom et al, 1989).  It is this core, or "nucleoid”, that is injected into 
host cells to propagate infection (Knipe and Howley, 2001).  The inner core is surrounded 
by the matrix protein (MA, p17), which provides both the structural and vital integrity of 
the virion (Gelderblom et al, 1989).  Other proteins which are proposed to be contained 
within the viral core include the viral protein vif, on the order of 1 molecule per every 20-
30 molecules of p24 (Liu et al, 1995), and the accessory protein nef, which is thought to 
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be present on the order of ~10% of RT incorporation (Welker et al, 1996).  Their 
presence in the core suggests that they play an important role in early infection.  The core 
and matrix envelope are surrounded by a lipid membrane studded with the surface 
glycoprotein gp120 (SU) and the transmembrane glycoprotein gp41 (TM), which act as 
binding sites for receptors on host cells so as to initiate infection.  Figure 2 illustrates the 
structure the HIV-1 virion. 
A.      B.  
 
 
  
 
 
 
 
Figure 2: HIV-1virion structure.  (A) Scanning micrograph of budding HIV-1 particles on the 
surface of a T-lymphocyte.  Notice the cone shaped core of each virion (Levy, 1998).  (B) Schematic of 
the HIV-1 virion structure.  Each component of the infectious virion is listed (Levy, 1998). 
 
 
 HIV-1 Infection 
 HIV is transmitted either by exposure to the oral, rectal or vaginal mucosa during 
sex or breast feeding, by intravascular inoculation with infected blood products, or by 
maternal transmission from mother to child (Jaffe et al, 1983).  Three primary factors 
influence established infection of HIV-1 including the characteristics of the infectious 
agent (virulence and infectiousness), host related factors (susceptibility, contagiousness 
and immune response) and environmental factors (social, cultural and political) (Levy, 
 8
1998).  These factors contribute to the uniqueness of each virus between hosts.  They also 
contribute to the classifications HIV based on the extent of infection. 
   
  Classification of Infection 
 HIV infection can be classified on the basis of three distinct characteristics.  The 
replication rate of the virus has been delineated to be either that of the “slow/low” type, 
which refers to the fact that the virus replicates slowly and produces a low amount of 
infectious progeny, or “fast/high” which confers to the exact opposite scenario (Fenyo et 
al, 1988).  Slow/low progression can often lead to an infection classified as a long-term 
non-progressor (LTNP), in which the viral loads of the host seem characteristic of HIV, 
but the number of viable CD4 T-cells remains fairly constant (Learmont et al, 1992).  
Slow/low infection is also often associated with a Vif deficient virus replicating in non-
permissive cells (which will be explained in further detail later in the paper, and relates 
directly to this MQP).   
 HIV infection can also be classified based on the formation of syncytium in host 
cells (Koot et al, 1992).  Syncytium is the formation of multinucleated giant cells induced 
by cell:cell fusion (see Figure 3) (Levy, 1998).  Syncytium inducing viruses (SI) are 
usually associated with advanced infection, while non-syncytium inducing viruses (NSI) 
are associated with “slow/low” replicating viruses.   
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Figure 3: Syncytia formation caused by cell:cell 
 fusion during acute infection of PBMC by HIV-1 (Levy, 1998). 
  
 
 Lastly, the virus can be classified by its stages of infection.  Tropism refers to the 
cell lines in which the virus establishes infection.  M-tropic strains of HIV-1, which are 
mainly present in early infection, are associated with a slow/low rate of replication.  They 
reproduce primarily in monocyte-derived macrophages.  T-tropic viruses replicate 
primarily in CD4 t-cells, and are associated with fast/high replication (Collman et al, 
1989).  T-tropic infection is usually established after long-term incubation of the virus 
and is associated with the later stages of infection.  It accounts for the characteristic 
reduction in CD4 counts among HIV infected patients. 
   
Viral Entry 
Infection by an HIV-1 virion begins with the binding of the surface glycoprotein 
gp120 to the CD4 receptor of the host cell (Dalgleish et al, 1984).  Binding of soluble 
CD4 to gp120 results in the rapid dissociation of gp120 from its complex with the 
transmembrane glycoprotein gp41 (Moore et al, 1990).  CD4, however, is not the only 
cell surface receptor needed for viral entry.  Research proved that the β-chemokine 
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receptor CC-CKR-5 (CCR-5) was the principle co-factor for the entry of m-tropic viruses 
into cells (Deng et al, 1996).  Conversely, complementary DNA cloning proved that 
Fusin (now dubbed CXCR-4) was the co-receptor for t-tropic HIV-1 infection (Reng et 
al, 1996).  The dissociation of gp120 allows it to bind a co-receptor, such as CCR-5, 
which brings the virion closer to the cell surface.  Exposure of gp41 allows it to bind a 
fusion receptor, which permits the fusion of the virion to the cells (Sattentau and Moore, 
1991).  After the virion has bound to the hosts’ receptors, it fuses with cell in a pH 
independent manner (McClure et al, 1988) and injects the core nucleoid into the 
cytoplasm of the host cell (see Figure 4). 
 
Figure 4: Interactions between the HIV-1 virion and the host cell surface.  (A) The binding site on 
HIV-1 gp120 (red) interacts with the host cells’ CD4 receptor (yellow).  (B) Dissociation of gp120 
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allows it to bind a co-receptor, such as CCR-5 (turquoise), and that dissociation results in (C) the 
exposure of gp41 (green).  (D) Exposure of gp41 allows it to bind a fusion receptor (blue) on the cell 
surface which allows the virion (E) to enter the host cell and propagate infection.  (Levy, 1998). 
 
  HIV-1 Genome 
 Once the viral core has been injected into the host cell, the propagation of the 
virus can begin.  The 9.8 kb HIV genome contains open reading frames (ORF’s) 
encoding several viral proteins (see Figure 5) (Levy, 1998).   
 
 
 
 
 
  
Figure 5: HIV-1 Open Reading Frames.  The location of each gene, the 
relative size of the primary translation products, and the processed 
mature viral proteins are shown (Knipe, 2001). 
 
 Reverse transcription of the viral genome occurs within subviral particles in the 
cytoplasm of the host cell (Knipe, 2001).  The double stranded DNA product is then 
transported to the nucleus by a nucleoprotein-preintegration complex (PIC) where 
integration into the chromosomal DNA, mediated by the virus-encoded integrase protein, 
takes place (see Figure 6) (Brown et al, 1987).  Once the viral DNA has been 
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incorporated into the host cells DNA,  production of viral mRNA begins, followed by the 
translation of proteins needed to construct infectious progeny.  Initially, the full length 
viral mRNA is translated into the gag and pol precursors, which are proteolytically 
cleaved into the matrix (MA, p17), capsid (CA, p24) and nucleocapsid proteins (NC, p6 
& p9) (from gag precursor), protease (P, p10), reverse transcriptase (RT, p66, p51), and 
integrase (IN, p32) (from gag-pol polyprotein) (see Figure 5) (Gelderblom et al, 1989).  
The envelope precursor protein (gp16) is then cleaved into the surface glycoprotein (SU, 
gp120) and the transmembrane glycoprotein (TM, gp41) (McCune et al, 1988).  Other 
viral regulatory and accessory proteins such as Tat (p14), Tev (p26), Rev (p19), Nef 
(p27), vif (p23), vpr (p15) and vpu (p16) are not processed until later in infection (Levy, 
1998).   
 
Figure 6: Viral life cycle.  (1) Virion binds CD4 and respective fusion receptor and (2) the virion fuses 
to the host cell in a pH independent manner, releasing its encapsidated genome into the cytoplasm.  
(3) Partial uncoating of the virions is followed by the (4) reverse transcription of its double stranded 
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RNA genome in a subviral particle in the cytoplasm.  (5) The resulting double stranded DNA is then 
transported to the nucleus where integration into chromosomal DNA takes place.  (6) Viral mRNA’s 
are then transcribed from the chromosomal DNA and (7) translated into the viral proteins.  (8)  The 
translated Env, Gag and Pol proteins assemble and (9) are transported to an area near the surface of 
the cell.  (10) Viral progeny particles  begin budding off the surface of the host cell.  (11) Subsequent 
proteolysis by the viral protease allows for the release of mature virions.  (12) Non-virion associated 
gp120 is also released from the cells  (Knipe and Howley, 2001). 
 
 After the production of the viral proteins, newly synthesized genomic RNA is 
incorporated into the capsid protein, which had been previously translated in the 
cytoplasm, and the gag-pol proteins are processed near the cell surface (Knipe, 2001).  
This gives rise to the to production of a new infectious virion which then buds through 
the host cell membrane and is released to subsequently infect other cells in the same 
manner (Levy, 1998).   
 
HIV-1 Virion Infectivity Factor (vif) 
 The HIV-1 accessory gene vif encodes a basic protein of 192 amino acids with a 
molecular weight of approximately 23 kDa (Kan et al, 1986).  The translated protein is 
predominantly localized to the cytoplasm, but some presence of the protein has been 
linked to the nucleus as well, indicating that Vif is involved in some kind of 
transcriptional mechanism. 
 The translated Vif protein has the ability to form multimers (Yang et al, 2001).  The 
portion of the genome responsible for this action falls between amino acids 154-164, and 
a deletion in this region dramatically reduced both the ability of the protein to form these 
multimeric factors and the efficiency of the virus to produce infectious progeny (Yang et 
al 2001).  Since this mutation affected the viruses ability to infect host cells, it suggests 
that Vif’s ability to form multimers is essential for its function.  This same domain 
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(ser144), which is adjacent to the proposed oligomerization domain, is phosphorylated, 
and a deletion mutation of that particular residue also severly reduces Vif’s funciton 
(Yang et al, 1996).  This suggests that the phosphorylation of Vif is also essential to its 
function. 
 Early research showed that the amino acid sequence of Vif was highly conserved 
among many different HIV-1 isolates, as well as in HIV-2 isolates, and in other 
lentiviruses (Strebel et al, 1987).  This sequence conservation lead scientists to believe 
that Vif played a vital role in the in the viral life cycle of HIV-1.  Viruses with a mutated 
vif gene, in most cases, showed rates of infectivity that were ~1000X less than that of the 
wild type virus.  However it was also shown that in some cell lines, the presence of vif is 
not required for infectivity (Strebel et al, 1987).     
 
 
A.  MENRWQVMIVWQVDRMRIRTWKSLVKHHMYVSGKARGWFYRHHYESPHPRISSEVHIPLGDAR 
LVITTYWGLHTGERDWHLGQGVSIEWRKKRYSTQVDPELADQLIHLYYFDCFSDSAIRKALLGHI 
VSPRCEYQAGHNKVGSLQYLALAALITPKKIKPPLPSVTKLTEDRWNKPQKTKGHRGSHTMNGH 
 
   B. 
 
Figure 7:  (A) Amino acid sequence of the HIV-1 accessory protein 
vif.  (B) Organization of open reading frames in HIV-1’s genome.  
(HIV Sequence Database--http://www.hiv.lanl.gov/content/hiv-
db/ALIGN_CURRENT/ALIGN-INDEX.html). 
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 With the idea that the expression of Vif is necessary for the infection of host cells, 
the function of the viral protein was investigated further.  PCR analysis using primers 
specific for viral RNA intermediates and DNA products of reverse transcription proved 
that Vif is required for the synthesis of proviral DNA (Schweldler et al, 1993).  
Transfection experiments using both WT and ∆vif viruses showed that Vif is also 
required for the production of infectious virions in certain cell lines (Schweldler et al, 
1993).  The latter lead to the discovery of the two primary phenotypes of host cells for 
HIV-1.  Cell lines, such as macrophages, H9 T-lymphatic cells and CEM cells, in which 
the presence of Vif was crucial to produce infectious progeny were labelled as “non-
permissive”; and those cell lines, such as Sup-T1 and Jurkat, which produced infectious 
virions even in the absence of vif were deemed “permissive” (Schweldler et al, 1993).  
This finding proved that the ∆Vif phenotype was cell specific.  Heterokaryon 
experiments also proved that the non-permissive phenoype is dominant over the 
permissive phenotype; meaning that Vif deficient virions produced in non permissive 
cells who infect permissive cells create non infectious progeny (Madani and Kabat, 
1998).  This finding suggests either the presence of a host cell factor in non-permissive 
cells that counteracts the effects of Vif, or a cell factor in permissive cell lines that 
functions similarly to Vif in its absence. 
 Experiments performed by Schweldler et al  (1993) (see Figure 8),  proved that 
when vif was mutated in HIV-1 strains and transfected into non-permissive, human 
PBL’s or macrophages, which are primary cell resivoirs for HIV-1 in vivo, the virions 
produced were nearly completely defective. 
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A.  
                                    
         
 
B.  
Figure 8: (A) Infectivity of wild type and ∆vif 
viruses in different cell lines of both  
permissive and non-permissive phenotypes.    
The target cells shown were exposed to 
filtered supernatants of COS cells transfected 
with the WT or ∆vif proviral constructs and 
were then monitored for the production of 
HIV-1 p24 antigen to assess infectivity. (B)  
Infectivity of wild type and ∆vif viruses in a 
non-permissive cell line.  CEM cells were 
infeted with WT or ∆vif viruses and then 
cocultivated with H9 cells.  As before, 
production of the  p24 antigen was monitered 
to assess infectivity  (Schweldler, 1993). 
 
 The mechanism by which this phenomenom was carried out was shown to be linked 
with the reverse transcription of genomic RNA into proviral DNA.  As stated previously, 
PCR analysis proved that proviral DNA synthesis was impaired in ∆vif virions 
(Schweldler et al, 1993).  Further investigation (see Figure 9) showed that the amounts of 
reverse transcriptase and genomic RNA were relatively the same for both wild type and 
∆vif viruses, but the production of proviral DNA from HIV-1 genomic RNA, in non-
permissive cells, was significantly reduced in ∆vif viruses (Schweldler et al, 1993).  This 
proposed the question, is the viral DNA being degraded during or after synthesis, or is it 
even being synthesized at all?   
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D.     
Figure 9: PCR analysis of proviral DNA synthesis and 
analysis of RNA content.  (A) HIV-1 specific PCR 
primers used to amplify proviral DNA.  (B) Time course 
analysis of viral DNA synthesis in non-permissive H9 
cells after exposure to WT and ∆vif viruses grown in 
permissive SupT1 cells.  (C) Time course analysis of 
viral DNA synthesis in non-permissive H9 cells after 
exposure to WT and ∆vif viruses grown in non-
permissive CEM cells.  (D) RNA content of WT and ∆vif 
virions.  RNA was extracted fom both WT and ∆vif 
virions and then normalized for p24 antigen content.  
(Schweldler et al, 1993)    
 
 Next, the mechanism by which Vif might possibly synthesize or protect nascent 
proviral DNA was investigated.  Research showed that a defective virus can enter cells 
and begin reverse transcription during primary infection, but the resulting viral DNA is 
prematurely degraded, redering it unable to cause further rounds of infection.  This 
defectiveness of the vif mutant must, therefore, be dependent on the cellular source of the 
virus (Madani and Kabat, 1998).    With that in mind, that same group investigated the 
permissive and non-permissive cell phenotypes.  The fact that vif deficient viruses 
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produced in permissive cells still had the ability to produce infectious virions, while those 
produced in non-permissive cell lines did not, suggested that there was a cellular co-
factor expressed in non-permissive cells that was overcome by vif in non-permissive 
cells.  This cellular cofactor was discovered via subtractive cloning techniques to be 
CEM15 (now known as apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-
like 3G or APOBEC3G) (Sheehy et al, 2002).  The presence of this protein in non-
permissive cells, but its absence in permissive lines, proved that there was a cellular 
inhibitor which is overcome by vif in non-permissive cell lines (Sheehy et al, 2002).   
 In non-permissive cells expressing Apobec3G, WT viruses (expressing vif) 
replicate normally (see Figure 10) while vif deficient viruses show impaired replication.  
Conversely, in permissive cells transgenically expressing Apobec3G, both ∆vif and wild 
type viruses are able to replicate normally (Sheehy et al, 2002). 
A.              B. 
Figure 10: Expression of CEM15 (APOBEC3G) in permissive and non permissive cell lines.  (A) 
Replication of  HIV-1 in permissive and non-permissive cells.  CEM (non-permissive) and CEM-SS 
(permissive) cells were infected with WT or ∆viruses, and p24 antigen accumulation was monitored 
to assess viral replication.  (B) Northern blot analysis of the expression of CEM15 in permissive and 
non-permissive cell lines.  RNA’s from the listed cells were extracted and resolved by electrophoresis.  
(Sheehy et al, 2002) 
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 Ectopic expression of genes from non-permissive cells in permissive cell lines, an 
event that occurs when a virion produced in a non-permissive cell infects a permissive 
cell, converts them to a nonpermissive phenotype, further supporting the fact that the 
non-permissive phenotype is dominant; and Apobec3G can be incorporated into virions, 
which may account for the ability of the protein to change the phenotype of the cell 
(Sheehy et al, 2002).   
 Sheehy et al also noticed that the nucleotide sequence of Apobec3G was similar to 
that of Apobec1, a cytidine deaminase.  This observation proved to be relevant when later 
research showed that HIV-1 DNA is a target substrate for Apobec3G (Zhang et al, 2003).  
The confirmation that Apobec3G was, in fact, a cytidine deaminase that induced G to A 
hyper-mutation in the minus strand of proviral DNA, gave insight into the protein’s 
native function.  This DNA mutator may play an active role in  the viral defense 
mechanism in host cells that can induce lethal hyper-mutation of the incoming nascent 
viral reverse transcripts.  It is thought that this hyper-mutation accounts for the ∆vif 
phenotype (Zhang et al, 2003).   
 Sheehy et al states, “Because DNA deamination takes place after virus entry into 
target cells, Apobec3G function is dependent on its association with the viral 
nucleoprotein complexes that synthesize cDNA and must therefore be incorporated into 
virions as they assemble in infected cells.”  This group also discovered that packaging of 
3G was almost eliminated in WT virions, and that levels of 3G in infected cells was also 
reduced (but not to the same degree as in the virions) (see Figure 11).  Protease inhibitor 
experiments proved that the direct interaction of  Vif with Apobec3G in host cells, 
resulted in the induction of proteosome-mediated degredation.  
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Figure 11: Vif inhibits the packaging of Apobec3G into virions while also effectively binding it in host 
cells.  (a & b) Levels of Apobec3G in host cell lysates as well as virions.  293 T-cells were transfected 
with varying amounts of plasmids containing Apobec3g and either WT or ∆vif viruses.  Occlusion of 
Apobec3G was monitored.  (c) Permissive cells’ production of vif vs. Apobec3G.  CEM-SS 
(permissive cell line) cells expressing Apobec3G were challenged with WT HIV-1 and the 
intracellular levels of Apobec3G were monitored.  (d) Immunoblot analysis of 293 T-cells transfected 
with vectors containing WT or ∆vif viruses and a constant amount of Apobec3G.  The intracellular 
levels of both vif and Apobec3G were monitored.  (Sheehy et al, 2003). 
 
 
 The current theory for the function of vif is that it has the ability to both partially 
exclude Apobec3G from being packaged into virions and also signal for it’s proteosomal 
degradation through a direct interaction (Sheehy et al, 2003).  The binding of Apobec3G 
by vif in the host cell enables the production of proviral DNA and subsequent infection of 
other cells.  It is for this reason that my research has centered around this topic.  The 
primary reservoir for HIV-1, as stated  before, is in non-permissive cells, and by 
disabling Vif’s function, you can almost completely block infection of HIV-1.   
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PROJECT PURPOSE 
 
 It has been speculated that the viral protein vif evolved in an effort to protect HIV-
1 from the human body’s natural viral defense systems.  Subsequent research validated 
this fact and gave insights into the mechanisms by which this feat was accomplished.  
Now with the knowledge that Vif binds the host cell cytidine deaminase, Apobec3G, in 
an effort to protect the minus strand of the reverse transcripts from being prematurely 
degraded, this Apobec3G-induced viral destruction mechanism was selected as a possible 
target for anti-retroviral therapies.  The main goal of my research was to identify a novel 
technique for the expression and purification of Apobec3G, so as to use it for structural or 
biochemical studies which could give insights into the mechanisms of HIV-1 and the 
human body’s innate anti-viral defense.  Targeting Vif for these experimental therapies 
could prove to be useful knowing that Vif deficient viruses in non-permissive cells 
(which are the primary reservoir for HIV-1 in vivo) are unable to produce infectious 
progeny.  Many of the processes in which Vif participates in are still somewhat obscure, 
and the knowledge gained from this research could prove to be valuable in the 
identification of targets for experimental therapies.   
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MATERIALS AND METHODS 
Expression of Apobec3G 
Apobec3G-encoding plasmid constructs were created with KpnI forward and reverse 
primers.  The cDNA constructs, which were amplified using the polymerase chain 
reaction (PCR), and the pDuet vectors were then digested with KpnI.  The Novagen® 
pDuet vectors were digested in a total volume of 25 µL as follows: 10 µl pDuet Vector, 
2.5 µL Buffer I (NEB buffer), 2.5 µL KpnI, 10 µL sterile water.  The PCR products were 
digested in a total volume of 50 µL as follows: 35 µL 3G PCR product, 5 µL Buffer I, 
5 µL KpnI, 5 µL sterile water.  Each reaction was incubated in a 37°C water bath for 1 
hour and the products were purified using the Qiagen® PCR purification kit.  The PCR 
products were ligated into the pDuet vectors as follows: 13 µL purified Apobec3G cDNA 
insert, 3 µL digested pDuet vector, 2 µL T4 Buffer, 2 µL T4 Ligase (total volume of 20 
µL).  The ligation reaction was incubated at room temperature for ~1.5 hours.  To 
transform the ligations into cells for expression, 7 µL of the ligation reaction was added 
to 100 µL of competent BL-21 (DE3) cells and incubated on ice for 30 minutes (tapping 
the tube occasionally).  The reaction was then heat shocked for 90 seconds at 42°C to 
“open” the cell walls, and then an incubation at room temperature for ~5 minutes will 
“close” the cell walls and ensure transformation.  1 mL of LB media was then added to 
the cells, and the entire reaction was plated on LB plates containing Chloroamphenicol 
(since the pDuet vector confers chloroamphenicol resistance) and were incubated a 37°C 
overnight.  Once colonies had grown, “over-night” cultures were prepared as follows, 50 
mL Terrific Broth (TB) medium, 50 µL of Chloroamphenicol, 1 colony from previously 
plated cells.  Those cultures (10 were made) were then incubated on a shaker overnight at 
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37°C.  After 24 hours, the 50 mL overnight cultures were each added to a liter of TB 
media with 1 mL of chloroamphenicol.  Those 1-liter cultures were incubated at 37°C 
until the cells were in log phase.  To determine when the cells were growing in log phase, 
the absorbance of each culture was taken, and an OD600 reading between 0.6-0.8 indicated 
log phase growth.  Once log phase had been reached, the temperature was re-set to 28°C 
(which was found to be the optimal temperature) and the cultures were allowed to 
equilibrate for 30 minutes.  Expression of Apobec3G was induced using 300 µΜ IPTG 
(which was found to be the ideal concentration of IPTG).  After induction, the cultures 
were allowed to grow for another 3 hours (which was discovered to be the optimal 
allowed time for growth), and then harvested by spinning at 5000 rpm for 30 minutes.  
The pellets were then resuspended in 50 mM NaP, 300 mM NaCl, 10 mM Imidazole and 
transferred to a 50 mL conical tube where they were spun again at 5000 rpm for 20 
minutes.  The supernatant was then decanted, and the pelleted cells, now expressing 
Apobec3G, were stored at -80°C. 
 
Lysing of Apobec3G Pellets 
 Bacterial cell pellets were thawed and then resuspended in 25 mL of 50 mM NaP, 
300 mM NaCl, 10 mM Imidazole, 1 mM DTT, 1 mM PMSF.  Cells were then lysed by 
submitting them to one pass through the cell disruptor, which lyses the cells via intense 
pressure. 
Purification of Apobec3G Using HIS-Select Nickel Affinity Gel 
Lysed Apobec3G pellets were incubated with HIS-Select Nickel resin, and rocked on 
a nutator in the cold, for 45 minutes to 1 hour.  With the HIS-tagged proteins now bound 
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to the nickel beads, the suspension was poured onto a gravity column and the 
“flowthrough” was collected.  The resin was then washed with 10 bed volumes (50 mL) 
of 50 mM NaP, 300 mM NaCl, 10 mM Imidazole, 1 mM DTT, 1 mM PMSF, and the 
“wash” sample was also collected.  The fusion protein was eluted off of the beads by 
washing the bed with 50 mM NaP, 300 mM NaCl, 250 mM Imidazole, and this “elution” 
sample was collected in ~0.5 mL fractions.  The beads were then washed again with 50 
mM NaP, 300 mM NaCl, 10 mM Imidazole to ensure the viability of the resin. 
 
Purification of Apobec3G Using High Performance Q Sepharose Beads 
The purified protein was first diluted with Tris-HCl pH 8.0 in a 1:3 ratio, filtered into 
a 150 mL “superloop” and then loaded onto a mq10 ion exchange column.  The column 
was first equilibrated with 5 column volumes of 100% 20 mM Tris-HCl pH 8.0, 1 M 
NaCl, 1 mM DTT and then with the same buffer containing 5% as much NaCl salt as 
originally (all other components of the buffer are exactly the same).  The FPLC was then 
set using the following parameters: flow rate--4.0 mL/min, column pressure limit--4 Mpa, 
wavelength--280nm, eluate fraction size--2 mL, and with the gradient using a starting 
concentration of 15% 20 mM Tris-HCl pH 8.0, 1 M NaCl, 1 mM DTT and a target 
concentration of 85% 20 mM Tris-HCl pH 8.0, 1 M NaCl, 1 mM DTT.  Using the elution 
profile created by the FPLC,  fractions were analyzed via an SDS-PAGE gel to detect the 
presence of the fusion protein.  Those fractions containing the Apobec3G fusion were 
then pooled and further purified. 
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Purification of Apobec3G Using S-Protein Agarose 
 The protein fraction from the FPLC which conferred the greatest presence of the 
fusion protein on the SDS-PAGE gels was incubated with 0.5 mL of S-Agarose on the 
nutator in the cold for 45 minutes.  The reaction was then spun at 5000 rpm for 10 
minutes, and the supernatant was saved as the “flowthrough” fraction.  The beads were 
then resuspended in 2 bed volumes (1 mL) of 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 
1% Triton X-100, 1 mM DTT, and spun again at 5000 rpm for 10 minutes.  The “wash” 
step was repeated two more times.  To elute the protein, the beads were resuspended in 
200 mM NaCitrate pH 2 (made in 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-
100), spun for 10 minutes at 5000 rpm, and the supernatant was saved as the eluted 
protein sample. 
 
 Purification of Apobec3G Using a PD-10 Sizing Column 
 The column is first equilibrated with 25 mL of 20 mM HCl, pH 8.0, 500 mM NaCl.  
The protein sample (which had already been purified by the previously described 
methods) was then passed through the resin and bound to the beads.  The column was 
then eluted with 3.5 mL of the same buffer.  The PD-10 column also serves to change the 
buffer of a protein sample in solution. 
 
 Co-Immunoprecipitation of Vif and Apobec3G 
 The initial part of this experiment deals with the binding of Vif and Apobec3G.  The 
two proteins were incubated in the cold on a nutator overnight in a 1:3 ratio (25 µL of 
purified Vif fusion protein and 50 µL of purified Apobec3G fusion protein --> this was 
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done twice).  Each reaction was then incubated with either anit-Vif or anti-3G antibodies 
overnight in the same manner.  To bind the binding reaction to the protein A agarose, the 
resin was first equilibrated with 50 mM NaP, 300 mM NaCl, 10 mM Imidazole, and was 
then incubated overnight in the same manner with the bound fusion proteins containing 
the given antibodies.  To assay the reaction via SDS-PAGE gel and by western blotting, 
the gel was washed three times with 50 mM NaP, 300 mM NaCl, 10 mM Imidazole, and 
50 µL of the same buffer was added to the reaction again.  25 µL of this was run on an 
SDS-PAGE gel without dye, for western blotting, and 25 µL of loading dye (without 
reducing agent) was added to the remainder of the reaction to be assayed by SDS-PAGE.  
The SDS gel and Western blot film were then observed for the presence of the bound Vif-
3G fusion protein. 
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RESULTS 
  
Expression of Apobec3G 
The main purpose of this MQP was to identify a novel technique for the 
expression and purification of soluble Apobec3G for use in structural and biophysical 
studies.  A protocol for the expression and purification of Apobec3G was devised using a 
NusA-Apobec3G fusion protein.  In addition, a potential protocol for the cleavage of the 
fusion protein was devised, which would leave free purified Apobec3G.   
 To begin, I first had to identify an ideal environment in which to express the 
protein.  The human Apobec3G cDNA was amplified from another stock plasmid using 
PCR, and cloned into the Novagen® pDuet plasmid expression vector using KpnI 
restriction sites.  The successful cloning was confirmed via sequencing – data not shown.   
 
Figure 12:  Expression Vector and Primers Used for Expression.  (A) 
Novagen® pDuet vector used for expression.  The human Apobec3G cDNA 
sequence was cloned into the MCS-1 (multiple cloning site 1 – highlighted in 
red) and then transformed into competent BL-21 cells.  (B) Primers used to 
amplify Apobec3G DNA.  Primers were constructed with Kpn1 forward and 
reverse primers, and Apobec3G DNA was amplified from stock plasmids 
using PCR. 
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 The expression plasmid encoding Apobec3G was then transformed into 
competent BL-21(DE3) CodonPlus cells as described in the methods section of this 
report.   Chloramphenicol-resistant colonies were then chosen based on their isolated 
positions on the agar plate, and 12 different isolates were cultured in 250 mL of TB 
(terrific broth) media.  I then selected a range of temperatures (18°C, 28°C & 37°C) in 
which to grow the cultures, and varying concentrations of isopropyl thiogalactoside 
(IPTG)  (50 µM, 300 µM, 600 µM & 1 mM) in which to induce expression of the protein 
(Table 1).  5 mL time points were taken before induction, every hour for 3 hours post-
induction and after overnight growth.   
18°C 28°C 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
50 µM 
IPTG 
300 µM 
IPTG 
600 µM 
IPTG 
1 mM 
IPTG 
50 µM 
IPTG 
300 µM 
IPTG 
600 µM 
IPTG 
1 mM 
IPTG 
----------------------------------------------------------------------------------------------- 
37°C 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture 
250 mL 
culture  
50 µM 
IPTG 
300 µM 
IPTG 
600 µM 
IPTG 
1 mM 
IPTG 
 
Table 1: Illustration of Expression Experiment.  Cultures were grown 
at varying temperatures, and expression was induced with differing 
molarities of IPTG to find the ideal environment in which to express 
Apobec3G. 
 
 
 The time point samples were then pelleted and resuspended in 100 µL of Tris –
EDTA (TE), pH 7.4 and transferred to 1.5 mL eppendorf tubes.  The cells were then 
lysed via a sonicator, which ruptures cells by utilizing high frequency vibrations.  After 
sonication, the samples were spun down to remove cell debris, and the supernatant 
(soluble fraction) was analyzed further.  Due to a low protein concentration as determined 
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by a Bradford assay, the protein samples were then precipitated using TCA to make sure 
that all proteins present in the solution would be visible on a gel.  Loading dye was added 
to each sample, and they were analyzed via SDS-PAGE gel (see Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: SDS PAGE Analysis of Apobec3G Expression.  The NusA-3G fusion protein has a 
molecular weight of 120 kDa (black arrow on the right).  The green band on the gel represents a MW 
of ~80 kDa and the magenta band represents a MW of ~165 kDa.  The samples in each lane are 
indicated in the tables below the gels, as well as the temperature at which the cultures were grown.  
In the last gel (37°C, 600 µM & 1 mM) the 600 µM overnight samplewas discarded due to a spill.  
This accounts for the missing lane. 
 
18°C 
M 
A 
R 
K 
E 
R 
50 
µM 
Pre 
 
50 
µM 
1hr 
50 
µM 
2hr 
50 
µM 
3hr 
50 
µM 
o/n 
300 
µM 
Pre 
300 
µM 
1hr 
300 
µM 
2hr 
300 
µM 
3hr 
300 
µM 
o/n 
28°C 
50 
µM 
Pre 
 
50 
µM 
1hr 
50 
µM 
2hr 
50 
µM 
3hr 
50 
µM 
o/n 
300 
µM 
Pre 
300 
µM 
1hr 
300 
µM 
2hr 
300 
µM 
3hr 
300 
µM 
o/n 
M 
A 
R 
K 
E 
R 
18°C 
600 
µM 
Pre 
 
600 
µM 
1hr 
600 
µM 
2hr 
600 
µM 
3hr 
600 
µM 
o/n 
M 
A 
R 
K 
E 
R 
1 
mM 
Pre 
1 
mM 
1hr 
1 
mM 
2hr 
1 
mM 
3hr 
300 
µM 
o/n 
28°C 
600 
µM 
Pre 
 
600 
µM 
1hr 
600 
µM 
2hr 
600 
µM 
3hr 
600 
µM 
o/n 
M 
A 
R 
K 
E 
R 
1 
mM 
Pre 
1 
mM 
1hr 
1 
mM 
2hr 
1 
mM 
3hr 
300 
µM 
o/n 
37°C 
M 
A 
R 
K 
E 
R 
50 
µM 
Pre 
 
50 
µM 
1hr 
50 
µM 
2hr 
50 
µM 
3hr 
50 
µM 
o/n 
300 
µM 
Pre 
300 
µM 
1hr 
300 
µM 
2hr 
300 
µM 
3hr 
300 
µM 
o/n 
37°C 
600 
µM 
Pre 
 
600 
µM 
1hr 
600 
µM 
2hr 
600 
µM 
3hr 
M 
A 
R 
K 
E 
R 
1 
mM 
Pre 
1 
mM 
1hr 
1 
mM 
2hr 
1 
mM 
3hr 
1 
mM 
o/n 
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 After analyzing the expression, I determined that cultures grown at 28°C for 3 
hours and induced with 300 µM IPTG proved to express Apobec3G the most efficiently 
relative to other bacterial proteins.   The presence of the fusion protein in the uninduced 
lanes are most likely due to a leaky promoter. 
 To confirm Apobec3G expression, a 1 L culture was expressed using the above 
criteria.  The cells were then purified over the HIS-Select Ni2+ resin, which binds to the 
6XHis tag expressed in the NusA-3G fusion protein.  The eluted fractions were then 
assayed via an SDS-PAGE and western blot (see Figure 14).   
 
 
 
 
 
 
 
 
Figure 14:  Purification of His-Tagged Protein.  Western blot using anti-apobec3g antibodies of 
expression trial at 28°C inducing with 300 µM IPTG after being purified over the HIS-Select Ni2+ 
resin.  The presence of the NusA-3G fusion protein (delineated by the red arrow) is clearly seen.  
Each lane is loaded with a fraction eluted off of the HIS-Select Ni2+ column. 
 
 As seen in the western blot film, the red arrow delineates the Apobec3G-Fusion 
protein.  The large band beneath that is the free NusA in the solution.  It is illuminated by 
the 2° Ab which the membrane was incubated with.  Protein purified from non-induced 
cultures are not shown. 
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After confirmation that Apobec3G was being expressed, I could concentrate on 
finding an ideal method in which to purify and cleave the NusA-3G fusion protein in 
order to provide free Apobec3G. 
 
Nickel Column Purification of Apobec3G 
 The purification of Apobec3G required the utilization of different affinity, sizing 
and ion exchange columns.  To begin, I first lysed one pellet from the 10 L culture and 
purified it over the HIS-Select Nickel resin.  The eluted fractions were then collected and 
analyzed via SDS-PAGE gel (see Figure 15). 
 
 
Figure 15:  Analysis of Nickel Column Fractions by 
SDS-PAGE.  The fusion band is delineated by the black 
arrow.  The table displays  the organizion of the lanes 
in the gel. 
 
 The band marked by the black arrow represents the Apobec3G-NusA fusion 
protein.  As seen previously, the large band beneath the fusion is free NusA.  Protein 
from non-induced culture is not shown. 
 
 
 
 
Organization of Lanes 
M 
A 
R 
K 
E 
R 
F 
R 
A 
C. 
1 
F 
R 
A 
C. 
3 
F 
R 
A 
C. 
5 
F 
R 
A 
C. 
7 
F 
R 
A 
C. 
9 
F 
R 
A 
C. 
11 
F 
R 
A 
C. 
13 
F 
R 
A 
C. 
15 
F 
R 
A 
C. 
17 
F 
R 
A 
C. 
19 
F 
R 
A 
C. 
21 
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Mono Q Column Purification of Apobec3G 
 After purifying the fusion protein over the nickel resin, I pooled Nickel column 
fractions numbers 9 through 19,  which contained the greatest amount of protein, and 
passed that sample over the High Performance Q-Sepharose beads using the Fast 
Performance Liquid Chromatography (FPLC).  These beads are anion exchangers, so 
they bind to proteins with a net negative charge (PI of Apobec3G ~ 5.4).  The peak 
fractions were assayed via SDS-PAGE electrophoresis (see Figure 16). 
A.       B. 
 
 
 
Figure 16: (A) Elution Profile From the Mono-Q 
Column.  Absorbance of each eluted fraction was 
taken at 280 nm, and the peaks correspond to the 
absorbance units in each fraction (B) Analysis of 
various column fractions by SDS-PAGE.  The 
fusion band is delineated by the black arrow. 
  
S-Tag Purification of Apobec3G 
Fractions 32-40 from the mono Q colunm were then pooled and passed over the 
S-protein Agarose which is specific to the S-Tag that is expressed as part of the NusA-
Apobec3G fusion protein.  The protein was eluted in one fraction, and 100 µL of that 
fraction was TCA precipitated and analyzed via SDS-PAGE electrophoresis (see Figure 
17).  This purification left us with a protein that was ~85% pure, so I then focused on 
cleavage trials to separate Apobec3G from its NusA-Tag. 
Organization of Lanes 
M 
A 
R 
K 
E 
R 
F 
R 
A 
C. 
28 
F 
R 
A 
C. 
30 
F 
R 
A 
C. 
32 
F 
R 
A 
C. 
34 
F 
R 
A 
C. 
36 
F 
R 
A 
C. 
38 
F 
R 
A 
C. 
40 
F 
R 
A 
C. 
50 
F 
R 
A 
C. 
59 
F 
R 
A 
C. 
61 
F 
R 
A 
C. 
66 
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Figure 17:  Analytical SDS-PAGE Gel of the Protein 
Eluted From the S-Protein Agarose Column.  The 
farthest lane to the left is the marker followed by the TCA 
precipitated eluate, then the non-precipitated fraction.  
The fusion protein is marked by the black arrow. 
 
 
 
Cleavage of Apobec3G 
 NusA-Apobec3G, which had now been purified over HIS-Select nickel resin, 
High Performance Q-Sepharose beads and S-Protein Agarose, was digested with the 
protease Thrombin at 1:25, 1:50 and 1:100 dilutions for 1 hr and 3 hr, respectively.  The 
reactions were stopped using 1 mM PMSF, and the samples were analyzed via SDS-
PAGE electrophoresis (see Figure 18).  The presence of free Apobec3G was confirmed 
by western blot.  This experiment, however has yet to be optimized further.  As one can 
see, from both the SDS-PAGE gel and the western blot, there is still some free NusA as 
well as some other contaminants that have to be eliminated before the protein can be used 
for structural or biochemical studies.  In addition, the experiment has yet to be optimized 
for protein yield.   
A.      B. 
 
  
 
 
 
 
 
 
 
Figure 18: (A) SDS-PAGE gel of thrombin digests of purified NusA-Apobec3G fusion protein.  Free 
Apobec3G has an approximate MW of 48 kDa and is delineated by the black arrow on the gel.  (B) 
Western blot of best cleavage reaction, which proved to be 1:25 digest for 1 hour.  The free protein is 
shown by the black arrow. 
  
Organization of Lanes 
M 
A 
R 
K 
E 
R 
1hr. 
1:25 
1hr. 
1:50 
1hr. 
1:100 
3hr. 
1:25 
3hr. 
1:50 
3hr. 
1:100 
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 The western blot confirms the presence of free Apobec3G, but, as can be seen 
from the gel, most of the protein remains in uncleaved form, so the protocol has still yet 
to be optimized further.  I speculate that by purifying the sample once more using a sizing 
column, most of the unwanted proteins still present in the solution could be eliminated 
(see Table 2).  Another pass through the S-Protein Agarose could also eliminate most of 
the free NusA.   
 
Purification and Cleavage Protocol 
Step 1 Step 2 Step 3 Step 4 Step 5 Step 6 Step 7 
Lyse 
pellet 
Purify 
over 
HIS-
Select 
Ni2+ 
Resin 
Purify 
over 
MonoQ 
Column 
using 
FPLC 
Purify 
over S-
Protein 
Agarose 
Cleave 
using 
1:25 
Thrombin 
for 3 hrs. 
Purify 
over 
PD-10 
sizing 
column 
Purify 
over S-
protein 
agarose 
Table 2:  Organization of Protocol for the Purification and Cleavage of the NusA-3G Fusion Protein.  
Steps in red are yet to be optimized.  The research only utilized up to step 5, but steps 6 & 7 are the 
proposed final procedures.  
   
Co-Immunoprecipitation of Vif and Apobec3G 
 Lastly, a co-immunoprecipitation experiment was done to prove that the 
Apobec3G being expressed is capable of binding HIV-1 vif.  To prove that Vif binds 
Apobec3G, and that this expression and purification produce functional Apobec3G, I co-
immunoprecipitated the two proteins and analyzed them via SDS-PAGE electrophoresis 
and western blot (see Figure 19).  This co-immunoprecipitation experiment suggests that 
Vif binds the bacterially expressed Apobec3G, indicating that Apobec3G at least retains 
its ability to bind vif. 
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A.    B. 
 
 
  
Figure 19: (A) SDS-PAGE analysis of Co-
Immunoprecipitation of Vif and Apobec 3G. The 
Vif-Apobec3G dimer has a MW of ~215 kDa.  The 
top blue band of the gel represents a MW of ~206 
kDa.  The Co-immunoprecipitated protein is 
delineated by the black arrow.  (B) Western blot 
of co-immunoprecipitation experiment.  As before, 
the black arrow arrow illustrates the Vif-3G 
dimer.   
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Organization of Lanes (A) 
M 
A 
R 
K 
E 
R 
Anti-
Vif 1° 
Ab 
Anti-
3G 1° 
Ab 
Organization of Lanes (B) 
Anti-
3G 1° 
Ab 
Anti-
Vif 1° 
Ab 
M 
A 
R 
K 
E 
R 
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DISCUSSION 
 
 The HIV-1 viral protein vif is a 23-kDa protein transcribed in the later stages of 
infection (Levy, 1998).  It was recently discovered that, once transcribed, Vif binds to the 
cytidine deaminase Apobec3G, which is readily translated in non-permissive cells (the 
primary reservoir for HIV-1 in vivo), and allows for the reverse transcription of the viral 
genome (Sheehy et al, 2003).  The reason this protein has been selected as a possible 
target for the creation of experimental therapies is because vif-deficient viruses, 
replicating in non-permissive cells, produce non-infectious viral progeny (Schweldler et 
al, 1993).  Therefore, a patient infected with a ∆Vif virus will show little or no presence 
of infectious virions in their body, and the number of viable CD4 T-cells will remain 
normal.  The body’s immune system will then not be affected, due to the fact that 
infectious viral progeny are not being produced.   
 The purpose of this MQP was to target the Vif-Apobec3G reaction in order to 
create experimental therapies for HIV-1.  From this research, I’ve proposed a novel 
technique for the expression and purification of Apobec3G.  Ideal conditions for the 
expression of the protein were determined to use the following criteria: expression was 
induced using 300 µM IPTG, and the cultures were grown for 3 hours at 28°C.  With that 
protocol, I then concentrated on the purification of Apobec3G.  The protein sample was 
purified using various affinity and ion exchange columns.  The developed process was 
determined to be as follows:  lysed pellet passed over the HIS-select Ni2+ column; eluted 
fractions pooled and passed through high performance Q-Sepharose beads; peak fractions 
pooled and passed over the S-Protein agarose; eluted protein cleaved using 1:25 thrombin 
for 3 hours at room temperature.  This protocol still has to be optimized further.  I 
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speculate that the cleaved protein can be purified further using the S-Protein agarose, 
which will bind all of the free NusA still present in the solution, and then using a sizing 
column which should eliminate the rest of the undesirable contaminants.  Once a sample 
of desirable concentration has been purified, the protein can be used for chemical and 
biophysical studies.  I propose to begin crystal trials and binding assays.  With these 
assays, insights into the structure and function of Apobec3G and Vif can be assessed.  
Investigating binding constant and rates can reveal the binding and active sites, which 
may serve as targets for possible experimental therapies.  This is the goal that this 
research inevitably strives to reach, and work will continue until definitive results have 
been achieved.     
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